GLP-1

glucagon-like peptide-1 (agonists) — The drug class behind Ozempic and Wegovy — obesity and diabetes treatments reshaping pharma pipelines and food-industry forecasts.

Coverage of GLP-1 is holding steady →: 2 signals on the latest tracked day, level with its three-week baseline of 2, across 2 domains. That makes it the #153 most-covered of the 157 concerns we track.

GLP-1 is steady by its own history. Its normal rhythm is about 2 signals a day across 2 domains. A real move would be a day at 3+ signals — 25% above that baseline, the bar our trend read calls accelerating ↑ — or a spread into domains beyond its usual 2. That is the move that would push it up the Wire. It sits on our Health & Bio Desk.